title: Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
abstract: Radiographic endpoints including response and progression are important for the evaluation of new glioblastoma therapies. The current RANO criteria was developed to overcome many of the challenges identified with previous guidelines for response assessment, however, significant challenges and limitations remain. The current recommendations build on the strengths of the current RANO criteria, while addressing many of these limitations. Modifications to the current RANO criteria include suggestions for volumetric response evaluation, use contrast enhanced T1 subtraction maps to increase lesion conspicuity, removal of qualitative non-enhancing tumor assessment requirements, use of the post-radiation time point as the baseline for newly diagnosed glioblastoma response assessment, and "treatment-agnostic" response assessment rubrics for identifying pseudoprogression, pseudoresponse, and a confirmed durable response in newly diagnosed and recurrent glioblastoma trials.
authors.affiliation: UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA. bellingson@mednet.ucla.edu.|Department of Radiological Sciences, University of California Los Angeles, Los Angeles, CA, USA. bellingson@mednet.ucla.edu.|Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. bellingson@mednet.ucla.edu.|UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, CA, USA. bellingson@mednet.ucla.edu.
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Ellingson
authors.affiliation: Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.affiliation: UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, CA, USA.|Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
authors.forename: Timothy F
authors.initials: TF
authors.lastname: Cloughesy
mesh_terms: D001921:Brain / Q000187:drug effects / Q000473:pathology; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000628:therapy*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D005909:Glioblastoma / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D007089:Image Enhancement; D007090:Image Interpretation, Computer-Assisted; D008279:Magnetic Resonance Imaging; D016896:Treatment Outcome
keywords: GBM; Glioblastoma; RANO; Response Assessment; T1 Subtraction